受孕及妊娠期母体使用生物制剂后的胎儿与母体结局:系统综述与Meta分析
该系统综述与Meta分析纳入35项研究、共11172例妊娠,比较慢性炎症性疾病(CID)女性妊娠期使用生物制剂(主要为TNF-α抑制剂)与疾病匹配对照及无CID妊娠的结局。汇总分析显示先天畸形、早产、严重新生儿感染、低出生体重、流产及子痫前期的合并比例在暴露组与疾病匹配组间均无统计学差异,GRADE证据确定性为低至极低。
要点
- 使用生物制剂的妊娠与疾病匹配对照相比,先天畸形、早产、严重新生儿感染、低出生体重、流产及子痫前期的合并比例均无统计学差异。
- 暴露组早产合并比例原文写作0.04(95%CI 0.10-0.14),与疾病匹配组0.10(95%CI 0.09-0.12)比较P=0.250。
- GRADE证据确定性为低至极低。
核心结论
- 使用GRADE方法评估,暴露于生物制剂的妊娠、疾病匹配对照及无CID妊娠的妊娠结局相当。
研究设计与样本
- 系统综述与Meta分析,检索PubMed和EMBASE数据库,检索时间范围为1998年1月至2021年7月。
- 纳入同行评议的英文队列研究、病例对照研究、横断面研究及含原始数据的病例系列。
- 共纳入35项研究,描述11172例妊娠。
- 由两名作者独立进行数据提取,采用随机效应模型对比例进行Meta分析,使用线性回归比较各暴露组间结局平均比例,以「治疗组」为参照类别。
- 所有研究均采用适当的质量评估工具评价,并使用GRADE方法评估证据总体确定性。
主要发现
- 先天畸形合并比例:治疗组0.04(95%CI 0.03-0.04;I²=77)vs 疾病匹配组0.04(95%CI 0.03-0.05;I²=86;P=0.238)。
- 早产合并比例:治疗组原文写作0.04(95%CI 0.10-0.14;I²=88)vs 疾病匹配组0.10(95%CI 0.09-0.12;I²=87;P=0.250)。
- 严重新生儿感染合并比例:治疗组0.05(95%CI 0.03-0.07;I²=88)vs 疾病匹配组0.05(95%CI 0.02-0.07;I²=94;P=0.970)。
- 低出生体重合并比例:治疗组0.10(95%CI 0.07-0.12;I²=93)vs 疾病匹配组0.08(95%CI 0.07-0.09;I²=0;P=0.241)。
- 流产合并比例:治疗组0.13(95%CI 0.10-0.15;I²=77)vs 疾病匹配组0.08(95%CI 0.04-0.11;I²=5;P=0.078);子痫前期合并比例:治疗组0.01(95%CI 0.01-0.02;I²=0)vs 疾病匹配组0.01(95%CI 0.00-0.01;I²=0;P=0.193)。
关键数值与推荐
- 各结局合并比例在治疗组与疾病匹配组间均无统计学差异。
- GRADE证据确定性为低至极低。
临床怎么用
- 原文未据此给出推荐。
局限性
- GRADE证据确定性为低至极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic medications, specifically tumour necrosis factor-α (TNF-α) inhibitors, have become increasingly prevalent in the treatment of chronic inflammatory disease (CID) in pregnancy. OBJECTIVE: To determine pregnancy outcomes in women with CID exposed to biologics during pregnancy. SEARCH STRATEGY: PubMed and EMBASE databases were searched through January 1998-July 2021. SELECTION CRITERIA: Peer-reviewed, English-language cohort, case-control, cross-sectional studies, and case series that contained original data. DATA COLLECTION AND ANALYSIS: Two authors independently conducted data extraction. A meta-analysis of proportions using a random-effects model was used to pool outcomes. Linear regression analysis was used to compare the mean of proportions of outcomes across exposure groups using the 'treated' group as the reference category. All studies were evaluated using an appropriate quality assessment tool. The GRADE approach was used to assess the overall certainty of evidence. MAIN RESULTS: Thirty-five studies, describing 11 172 pregnancies, were eligible for inclusion. Analysis showed pooled proportions for congenital malformations as follows: treated 0.04 (95% CI 0.03-0.04; I2 = 77) versus disease-matched 0.04 (95% CI 0.03-0.05. I2 = 86; p = 0.238); preterm delivery treated 0.04 (95% CI 0.10-0.14; I2 = 88) versus disease-matched 0.10 (95% CI 0.09-0.12; I2 = 87; p = 0.250); severe neonatal infection: treated 0.05 (95% CI 0.03-0.07; I2 = 88) versus disease-matched 0.05 (95% CI 0.02-0.07; I2 = 94; p = 0.970); low birthweight: treated 0.10 (95% CI 0.07-0.12; I2 = 93) versus disease-matched 0.08 (95% CI 0.07-0.09; I2 = 0; p = 0.241); pooled miscarriage: treated 0.13 (95% CI 0.10-0.15; I2 = 77) versus disease-matched 0.08 (95% CI 0.04-0.11; I2 = 5; p = 0.078); pre-eclampsia; treated 0.01 (95% CI 0.01-0.02; I2 = 0) versus disease-matched 0.01 (95% CI 0.00-0.01; I2 = 0; p = 0.193). No statistical differences in proportions were observed. GRADE certainty of findings was low to very low. CONCLUSION: We demonstrated comparable pregnancy outcomes in pregnancies exposed to biologics, disease-matched controls and CID-free pregnancies using the GRADE approach.
引用
- O'Byrne LJ, Alqatari SG, Maher GM, et al. Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: A systematic review and meta-analysis. BJOG. 2022. PMID: 35014759. doi:10.1111/1471-0528.17093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。